康方生物(09926.HK)依沃西與輝瑞(PFE.US)ADCs藥物開展聯合療法臨牀試驗

阿斯達克財經

2025/02/25

康方生物(09926.HK) 公布，公司自主研發的全球首創PD-1/VEGF雙特異性腫瘤免疫治療藥物依沃西單抗注射液，其國際市場開發合作伙伴Summit Therapeutics(SMMT.US) 已與美國輝瑞(PFE.US) 達成臨牀試驗合作，將共同推進依沃西與輝瑞多款抗體偶聯(ADCs)藥物在多種實體瘤中的聯合治療應用。根據協議條款，輝瑞將全面負責本次合作的系列臨牀試驗的開展，Summit...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2514862360"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514862360\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514862360?lang=zh_TW&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200914151047405_s.jpg","is_english":false,"pubTime":"2025-02-25 08:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514862360","market":"hk","top_or_hot":-1,"title":"康方生物(09926.HK)依沃西與輝瑞(PFE.US)ADCs藥物開展聯合療法臨牀試驗","media":"阿斯達克財經","content":"<div>\n<p>康方生物(09926.HK) 公布，公司自主研發的全球首創PD-1/VEGF雙特異性腫瘤免疫治療藥物依沃西單抗注射液，其國際市場開發合作伙伴Summit Therapeutics(SMMT.US)  已與美國輝瑞(PFE.US)  達成臨牀試驗合作，將共同推進依沃西與輝瑞多款抗體偶聯(ADCs)藥物在多種實體瘤中的聯合治療應用。根據協議條款，輝瑞將全面負責本次合作的系列臨牀試驗的開展，Summit...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1419847/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物(09926.HK)依沃西與輝瑞(PFE.US)ADCs藥物開展聯合療法臨牀試驗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物(09926.HK)依沃西與輝瑞(PFE.US)ADCs藥物開展聯合療法臨牀試驗\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯達克財經</strong><span class=\"h-time small\">2025-02-25 08:55</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>康方生物(09926.HK) 公布，公司自主研發的全球首創PD-1/VEGF雙特異性腫瘤免疫治療藥物依沃西單抗注射液，其國際市場開發合作伙伴Summit Therapeutics(SMMT.US)  已與美國輝瑞(PFE.US)  達成臨牀試驗合作，將共同推進依沃西與輝瑞多款抗體偶聯(ADCs)藥物在多種實體瘤中的聯合治療應用。根據協議條款，輝瑞將全面負責本次合作的系列臨牀試驗的開展，Summit...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1419847/latest-news/AAFN\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1419847/latest-news/AAFN\">阿斯達克財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1419847/latest-news/AAFN","article_id":"2514862360","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200914151047405_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1419847/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2514862360","pubTimestamp":1740444900,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"康方生物公布，公司自主研發的全球首創PD-1/VEGF雙特異性腫瘤免疫治療藥物依沃西單抗注射液，其國際市場開發合作伙伴Summit Therapeutics已與美國輝瑞達成臨牀試驗合作，將共同推進依沃西與輝瑞多款抗體偶聯藥物在多種實體瘤中的聯合治療應用。目前依沃西在全球開展臨牀試驗藥物均由康方生物生產供應。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","09926":"康方生物","03347":"泰格医药","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK1583":"高瓴概念","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC"},"translate_title":"Akeso Biologics (09926. HK) Ivoxi and Pfizer (PFE.US) ADCs launch combination therapy clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1,"03347":1},"content_text":"康方生物(09926.HK) 公布，公司自主研發的全球首創PD-1/VEGF雙特異性腫瘤免疫治療藥物依沃西單抗注射液，其國際市場開發合作伙伴Summit Therapeutics(SMMT.US)  已與美國輝瑞(PFE.US)  達成臨牀試驗合作，將共同推進依沃西與輝瑞多款抗體偶聯(ADCs)藥物在多種實體瘤中的聯合治療應用。根據協議條款，輝瑞將全面負責本次合作的系列臨牀試驗的開展，Summit將提供依沃西用於該系列臨牀試驗，雙方共同監督臨牀研究的進行，並各自保留其產品的相關權利。目前依沃西在全球開展臨牀試驗藥物均由康方生物生產供應。公司預期，本次與多種創新性ADCs藥物的聯合應用，將有助於更快速、更深入和充分地挖掘依沃西作為新一代腫瘤免疫治療雙抗新藥在全球市場的臨牀價值和商業價值，建立依沃西在腫瘤治療領域持續的迭代優勢。(gc/da)(港股報價延遲最少十五分鐘。沽空資料截至 2025-02-24 16:25。) (美股為即時串流報價； OTC市場股票除外，資料延遲最少15分鐘。)AASTOCKS新聞","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}